Technical Snapshots for These Medical Laboratories Stocks -- Exact Sciences, HTG Molecular Diagnostics, TrovaGene, and Novadaq Technologies

Friday, June 30, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 30, 2017 /PRNewswire/ --

If you want a Stock Review on EXAS, HTGM, TROV or NVDQ then come over to and sign up for your free customized report today. Ahead of today's trading session, observes the most recent performances of Exact Sciences Corp. (NASDAQ: EXAS), HTG Molecular Diagnostics
Inc. (NASDAQ: HTGM), TrovaGene Inc. (NASDAQ: TROV), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. Access's complimentary reports for today's stocks line-up at:

Exact Sciences 

Shares in Madison, Wisconsin headquartered Exact Sciences Corp. saw a decline of 2.60%, ending Thursday's trading session at $35.65. The stock recorded a trading volume of 2.46 million shares. The Company's shares have surged 51.32% over the last three months and 166.84% on an YTD basis. The stock is trading 10.02% and 62.28% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have a Relative Strength Index (RSI) of 56.44.

On June 22nd, 2017, Exact Sciences announced that it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening. Beginning at the American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the US to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk. Visit us today and access your complete report on EXAS for free at:

HTG Molecular Diagnostics 

Tucson, Arizona-based HTG Molecular Diagnostics Inc.'s stock declined 8.88%, closing the day at $2.77 with a total trading volume of 914,460 shares. The Company's shares have advanced 23.66% since the start of this year. The stock is trading 7.51% below its 200-day moving average. Additionally, shares of HTG Molecular Diagnostics, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have an RSI of 35.02.  

On June 28th, 2017, HTG Molecular Diagnostics announced that the Company has launched its new HTG EdgeSeq PATH Assay for sale in the US and Europe. The HTG EdgeSeq PATH Assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded sample availability is limited. The assay is designed to detect up to 470 mRNA targets, typically assessed by IHC. The complimentary research report on HTGM can be accessed at:


On Thursday, shares in San Diego, California headquartered TrovaGene Inc. recorded a trading volume of 3.15 million shares, which was higher than their three months average volume of 672,530 shares. The stock ended the day 9.17% higher at $1.31. The Company's shares have advanced 103.61% in the past month and 13.91% in the previous three months. The stock is trading above its 50-day moving average by 50.99%. Furthermore, shares of TrovaGene, which focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the US, have an RSI of 65.94.

On June 26th, 2017, TrovaGene announced that the US Patent and Trademark Office, and separately, the European Patent Office, have allowed claims for Patent Application 13/959739 and Patent Application EP10184598.0, respectively, entitled "Nucleophosmin Protein (NPM) Mutants, Corresponding Gene Sequences and Uses Thereof." These patents encompass NPM1 mutation detection and minimal residual disease monitoring of patients with acute myeloid leukemia. Register for free on and download the research report on TROV at:

Novadaq Technologies 

Mississauga, Canada headquartered Novadaq Technologies Inc.'s stock dropped 0.26%, finishing yesterday's session at $11.72. A total volume of 1.60 million shares was traded, which was above their three months average volume of 918,700 shares. The Company's shares have advanced 69.61% in the last one month, 53.40% in the previous three months, and 65.30% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 49.63% and 42.09%, respectively. Additionally, shares of Novadaq Technologies, which develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the US and internationally, have an RSI of 80.36.

On June 19th, 2017, Novadaq Technologies announced that it has entered into a definitive arrangement with Stryker Corporation, pursuant to which the latter has agreed to acquire all of the issued and outstanding shares of the Company for US$11.75 per share in cash, implying total equity value of approximately US$701 million. The transaction price represents premium of approximately 95.8% over the closing price of the NOVADAQ shares on the NASDAQ on June 16th, 2017. Download the report on NVDQ at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store